Loading…

The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease

Purpose [ 18 F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2024-05, Vol.51 (6), p.1662-1674
Main Authors: Gérard, Thomas, Colmant, Lise, Malotaux, Vincent, Salman, Yasmine, Huyghe, Lara, Quenon, Lisa, Dricot, Laurence, Ivanoiu, Adrian, Lhommel, Renaud, Hanseeuw, Bernard
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c426t-e0fc02d571cca609ab9eba1e4285e4cb4b41dc9fac574650c727ad76abc3592f3
container_end_page 1674
container_issue 6
container_start_page 1662
container_title European journal of nuclear medicine and molecular imaging
container_volume 51
creator Gérard, Thomas
Colmant, Lise
Malotaux, Vincent
Salman, Yasmine
Huyghe, Lara
Quenon, Lisa
Dricot, Laurence
Ivanoiu, Adrian
Lhommel, Renaud
Hanseeuw, Bernard
description Purpose [ 18 F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr). Methods [ 18 F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions ( Braak  ≤  2 , Braak  ≤  4 , and Braak  ≤  6 ) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values. Results The EOT in the Braak  ≤  2 region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R 2  + 0.08–0.09) with the best correlation observed for EOT in the Braak  ≤  4 region ( R 2  = 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values. Conclusions Quantifying [ 18 F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD.
doi_str_mv 10.1007/s00259-024-06603-2
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11043108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3045402733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-e0fc02d571cca609ab9eba1e4285e4cb4b41dc9fac574650c727ad76abc3592f3</originalsourceid><addsrcrecordid>eNp9kktuFDEQhlsIRELgAiyQJTZsGsrup1coihJABMFiWCFkVburpx167MF2TwgrrsEdOBUnwcOE4bFgY5dcn_9yuf4su8_hMQdongQAUckcRJlDXUORixvZIa-5zBto5c193MBBdieECwDeilbezg6KVqSg4YfZt8VILKwxGpwYfYpkI3MDizi7dDheMWfZO96evX_1Mq9FCdsMe3O6YGF0l4GF6J1dkmcYgtMmyST-0sSRabe0JpoNsTX5wfkVWk2BxRFtWlLNiLZH37N5HfEDsQ1OMzG_VWDGsuPp80hmRf77l6-B9SYQBrqb3RpwCnTvej_K3p6dLk6e5-evn704OT7PdSnqmBMMGkRfNVxrrEFiJ6lDTqVoKyp1V3Yl77UcUFdNWVegG9Fg39TY6aKSYiiOsqc73fXcrajX6VM8TmrtzQr9lXJo1N8Za0a1dBvFOZQFhzYpPLpW8O7jTCGqlQmapgktuTkoIXklJS9aSOjDf9ALN3ub-lMFlFUJoimKRIkdpb0LwdOwfw0HtXWD2rlBJTeon25QIl168Gcf-yu_xp-AYgeElNrO8Xft_8j-AMpqxL4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3045402733</pqid></control><display><type>article</type><title>The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease</title><source>Springer Link</source><creator>Gérard, Thomas ; Colmant, Lise ; Malotaux, Vincent ; Salman, Yasmine ; Huyghe, Lara ; Quenon, Lisa ; Dricot, Laurence ; Ivanoiu, Adrian ; Lhommel, Renaud ; Hanseeuw, Bernard</creator><creatorcontrib>Gérard, Thomas ; Colmant, Lise ; Malotaux, Vincent ; Salman, Yasmine ; Huyghe, Lara ; Quenon, Lisa ; Dricot, Laurence ; Ivanoiu, Adrian ; Lhommel, Renaud ; Hanseeuw, Bernard</creatorcontrib><description>Purpose [ 18 F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr). Methods [ 18 F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions ( Braak  ≤  2 , Braak  ≤  4 , and Braak  ≤  6 ) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values. Results The EOT in the Braak  ≤  2 region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R 2  + 0.08–0.09) with the best correlation observed for EOT in the Braak  ≤  4 region ( R 2  = 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values. Conclusions Quantifying [ 18 F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-024-06603-2</identifier><identifier>PMID: 38228971</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Aged, 80 and over ; Alzheimer Disease - diagnostic imaging ; Alzheimer's disease ; Biological Transport ; Biomarkers ; Brain ; Brain - diagnostic imaging ; Brain - metabolism ; Cardiology ; Cerebrospinal fluid ; Cognition ; Cognition &amp; reasoning ; Cognitive ability ; Correlation ; Diagnostic systems ; Disease ; Female ; Humans ; Imaging ; Isoquinolines ; Male ; Medicine ; Medicine &amp; Public Health ; Memory ; Middle Aged ; Missing data ; Neurodegenerative diseases ; Nuclear Medicine ; Oncology ; Original ; Original Article ; Orthopedics ; Pathology ; Positron-Emission Tomography ; Radiology ; Radiopharmaceuticals - pharmacokinetics ; Sensitivity analysis ; Signs and symptoms ; Standard scores ; Tau protein ; tau Proteins - metabolism ; Tauopathies - diagnostic imaging</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2024-05, Vol.51 (6), p.1662-1674</ispartof><rights>The Author(s) 2024. corrected publication 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. corrected publication 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024, corrected publication 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c426t-e0fc02d571cca609ab9eba1e4285e4cb4b41dc9fac574650c727ad76abc3592f3</cites><orcidid>0009-0009-3568-3474 ; 0000-0002-3102-6778 ; 0000-0003-0737-9220 ; 0000-0002-8613-2420 ; 0000-0003-0668-6122 ; 0000-0001-7997-3945 ; 0009-0006-6511-0819 ; 0000-0001-9139-2422 ; 0000-0002-8564-5136</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38228971$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gérard, Thomas</creatorcontrib><creatorcontrib>Colmant, Lise</creatorcontrib><creatorcontrib>Malotaux, Vincent</creatorcontrib><creatorcontrib>Salman, Yasmine</creatorcontrib><creatorcontrib>Huyghe, Lara</creatorcontrib><creatorcontrib>Quenon, Lisa</creatorcontrib><creatorcontrib>Dricot, Laurence</creatorcontrib><creatorcontrib>Ivanoiu, Adrian</creatorcontrib><creatorcontrib>Lhommel, Renaud</creatorcontrib><creatorcontrib>Hanseeuw, Bernard</creatorcontrib><title>The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>Purpose [ 18 F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr). Methods [ 18 F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions ( Braak  ≤  2 , Braak  ≤  4 , and Braak  ≤  6 ) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values. Results The EOT in the Braak  ≤  2 region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R 2  + 0.08–0.09) with the best correlation observed for EOT in the Braak  ≤  4 region ( R 2  = 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values. Conclusions Quantifying [ 18 F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnostic imaging</subject><subject>Alzheimer's disease</subject><subject>Biological Transport</subject><subject>Biomarkers</subject><subject>Brain</subject><subject>Brain - diagnostic imaging</subject><subject>Brain - metabolism</subject><subject>Cardiology</subject><subject>Cerebrospinal fluid</subject><subject>Cognition</subject><subject>Cognition &amp; reasoning</subject><subject>Cognitive ability</subject><subject>Correlation</subject><subject>Diagnostic systems</subject><subject>Disease</subject><subject>Female</subject><subject>Humans</subject><subject>Imaging</subject><subject>Isoquinolines</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Memory</subject><subject>Middle Aged</subject><subject>Missing data</subject><subject>Neurodegenerative diseases</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Pathology</subject><subject>Positron-Emission Tomography</subject><subject>Radiology</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Sensitivity analysis</subject><subject>Signs and symptoms</subject><subject>Standard scores</subject><subject>Tau protein</subject><subject>tau Proteins - metabolism</subject><subject>Tauopathies - diagnostic imaging</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kktuFDEQhlsIRELgAiyQJTZsGsrup1coihJABMFiWCFkVburpx167MF2TwgrrsEdOBUnwcOE4bFgY5dcn_9yuf4su8_hMQdongQAUckcRJlDXUORixvZIa-5zBto5c193MBBdieECwDeilbezg6KVqSg4YfZt8VILKwxGpwYfYpkI3MDizi7dDheMWfZO96evX_1Mq9FCdsMe3O6YGF0l4GF6J1dkmcYgtMmyST-0sSRabe0JpoNsTX5wfkVWk2BxRFtWlLNiLZH37N5HfEDsQ1OMzG_VWDGsuPp80hmRf77l6-B9SYQBrqb3RpwCnTvej_K3p6dLk6e5-evn704OT7PdSnqmBMMGkRfNVxrrEFiJ6lDTqVoKyp1V3Yl77UcUFdNWVegG9Fg39TY6aKSYiiOsqc73fXcrajX6VM8TmrtzQr9lXJo1N8Za0a1dBvFOZQFhzYpPLpW8O7jTCGqlQmapgktuTkoIXklJS9aSOjDf9ALN3ub-lMFlFUJoimKRIkdpb0LwdOwfw0HtXWD2rlBJTeon25QIl168Gcf-yu_xp-AYgeElNrO8Xft_8j-AMpqxL4</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Gérard, Thomas</creator><creator>Colmant, Lise</creator><creator>Malotaux, Vincent</creator><creator>Salman, Yasmine</creator><creator>Huyghe, Lara</creator><creator>Quenon, Lisa</creator><creator>Dricot, Laurence</creator><creator>Ivanoiu, Adrian</creator><creator>Lhommel, Renaud</creator><creator>Hanseeuw, Bernard</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0009-3568-3474</orcidid><orcidid>https://orcid.org/0000-0002-3102-6778</orcidid><orcidid>https://orcid.org/0000-0003-0737-9220</orcidid><orcidid>https://orcid.org/0000-0002-8613-2420</orcidid><orcidid>https://orcid.org/0000-0003-0668-6122</orcidid><orcidid>https://orcid.org/0000-0001-7997-3945</orcidid><orcidid>https://orcid.org/0009-0006-6511-0819</orcidid><orcidid>https://orcid.org/0000-0001-9139-2422</orcidid><orcidid>https://orcid.org/0000-0002-8564-5136</orcidid></search><sort><creationdate>20240501</creationdate><title>The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease</title><author>Gérard, Thomas ; Colmant, Lise ; Malotaux, Vincent ; Salman, Yasmine ; Huyghe, Lara ; Quenon, Lisa ; Dricot, Laurence ; Ivanoiu, Adrian ; Lhommel, Renaud ; Hanseeuw, Bernard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-e0fc02d571cca609ab9eba1e4285e4cb4b41dc9fac574650c727ad76abc3592f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnostic imaging</topic><topic>Alzheimer's disease</topic><topic>Biological Transport</topic><topic>Biomarkers</topic><topic>Brain</topic><topic>Brain - diagnostic imaging</topic><topic>Brain - metabolism</topic><topic>Cardiology</topic><topic>Cerebrospinal fluid</topic><topic>Cognition</topic><topic>Cognition &amp; reasoning</topic><topic>Cognitive ability</topic><topic>Correlation</topic><topic>Diagnostic systems</topic><topic>Disease</topic><topic>Female</topic><topic>Humans</topic><topic>Imaging</topic><topic>Isoquinolines</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Memory</topic><topic>Middle Aged</topic><topic>Missing data</topic><topic>Neurodegenerative diseases</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Pathology</topic><topic>Positron-Emission Tomography</topic><topic>Radiology</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Sensitivity analysis</topic><topic>Signs and symptoms</topic><topic>Standard scores</topic><topic>Tau protein</topic><topic>tau Proteins - metabolism</topic><topic>Tauopathies - diagnostic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gérard, Thomas</creatorcontrib><creatorcontrib>Colmant, Lise</creatorcontrib><creatorcontrib>Malotaux, Vincent</creatorcontrib><creatorcontrib>Salman, Yasmine</creatorcontrib><creatorcontrib>Huyghe, Lara</creatorcontrib><creatorcontrib>Quenon, Lisa</creatorcontrib><creatorcontrib>Dricot, Laurence</creatorcontrib><creatorcontrib>Ivanoiu, Adrian</creatorcontrib><creatorcontrib>Lhommel, Renaud</creatorcontrib><creatorcontrib>Hanseeuw, Bernard</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gérard, Thomas</au><au>Colmant, Lise</au><au>Malotaux, Vincent</au><au>Salman, Yasmine</au><au>Huyghe, Lara</au><au>Quenon, Lisa</au><au>Dricot, Laurence</au><au>Ivanoiu, Adrian</au><au>Lhommel, Renaud</au><au>Hanseeuw, Bernard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>51</volume><issue>6</issue><spage>1662</spage><epage>1674</epage><pages>1662-1674</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>Purpose [ 18 F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr). Methods [ 18 F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions ( Braak  ≤  2 , Braak  ≤  4 , and Braak  ≤  6 ) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values. Results The EOT in the Braak  ≤  2 region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R 2  + 0.08–0.09) with the best correlation observed for EOT in the Braak  ≤  4 region ( R 2  = 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values. Conclusions Quantifying [ 18 F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38228971</pmid><doi>10.1007/s00259-024-06603-2</doi><tpages>13</tpages><orcidid>https://orcid.org/0009-0009-3568-3474</orcidid><orcidid>https://orcid.org/0000-0002-3102-6778</orcidid><orcidid>https://orcid.org/0000-0003-0737-9220</orcidid><orcidid>https://orcid.org/0000-0002-8613-2420</orcidid><orcidid>https://orcid.org/0000-0003-0668-6122</orcidid><orcidid>https://orcid.org/0000-0001-7997-3945</orcidid><orcidid>https://orcid.org/0009-0006-6511-0819</orcidid><orcidid>https://orcid.org/0000-0001-9139-2422</orcidid><orcidid>https://orcid.org/0000-0002-8564-5136</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1619-7070
ispartof European journal of nuclear medicine and molecular imaging, 2024-05, Vol.51 (6), p.1662-1674
issn 1619-7070
1619-7089
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11043108
source Springer Link
subjects Aged
Aged, 80 and over
Alzheimer Disease - diagnostic imaging
Alzheimer's disease
Biological Transport
Biomarkers
Brain
Brain - diagnostic imaging
Brain - metabolism
Cardiology
Cerebrospinal fluid
Cognition
Cognition & reasoning
Cognitive ability
Correlation
Diagnostic systems
Disease
Female
Humans
Imaging
Isoquinolines
Male
Medicine
Medicine & Public Health
Memory
Middle Aged
Missing data
Neurodegenerative diseases
Nuclear Medicine
Oncology
Original
Original Article
Orthopedics
Pathology
Positron-Emission Tomography
Radiology
Radiopharmaceuticals - pharmacokinetics
Sensitivity analysis
Signs and symptoms
Standard scores
Tau protein
tau Proteins - metabolism
Tauopathies - diagnostic imaging
title The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A23%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20spatial%20extent%20of%20tauopathy%20on%20%5B18F%5DMK-6240%20tau%20PET%20shows%20stronger%20association%20with%20cognitive%20performances%20than%20the%20standard%20uptake%20value%20ratio%20in%20Alzheimer%E2%80%99s%20disease&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=G%C3%A9rard,%20Thomas&rft.date=2024-05-01&rft.volume=51&rft.issue=6&rft.spage=1662&rft.epage=1674&rft.pages=1662-1674&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-024-06603-2&rft_dat=%3Cproquest_pubme%3E3045402733%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c426t-e0fc02d571cca609ab9eba1e4285e4cb4b41dc9fac574650c727ad76abc3592f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3045402733&rft_id=info:pmid/38228971&rfr_iscdi=true